These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19319670)

  • 21. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-26a involved in Toll-like receptor 9‑mediated lung cancer growth and migration.
    Jiang DS; Wang YW; Jiang J; Li SM; Liang SZ; Fang HY
    Int J Mol Med; 2014 Jul; 34(1):307-12. PubMed ID: 24788552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients.
    Wang C; Cao S; Yan Y; Ying Q; Jiang T; Xu K; Wu A
    BMC Cancer; 2010 Aug; 10():415. PubMed ID: 20696081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic Human TLR9-LRR11 Peptide Attenuates TLR9 Signaling by Binding to and thus Decreasing Internalization of CpG Oligodeoxynucleotides.
    Pan X; Li B; Kuang M; Liu X; Cen Y; Qin R; Ding G; Zheng J; Zhou H
    Int J Mol Sci; 2016 Feb; 17(2):242. PubMed ID: 26907260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFκB pathway.
    Huang WT; Weng SW; Huang CC; Lin HC; Tsai PC; Chuang JH
    APMIS; 2012 Nov; 120(11):872-81. PubMed ID: 23009111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cpg-ODN, a TLR9 Agonist, Aggravates Myocardial Ischemia/Reperfusion Injury by Activation of TLR9-P38 MAPK Signaling.
    Xie L; He S; Kong N; Zhu Y; Tang Y; Li J; Liu Z; Liu J; Gong J
    Cell Physiol Biochem; 2018; 47(4):1389-1398. PubMed ID: 29929196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
    Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
    Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR9 signaling failure renders Peyer's patch regulatory B cells unresponsive to stimulation with CpG oligodeoxynucleotides.
    Booth JS; Arsenault R; Napper S; Griebel PJ; Potter AA; Babiuk LA; Mutwiri GK
    J Innate Immun; 2010; 2(5):483-94. PubMed ID: 20551621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TLR9-ERK-mTOR signaling is critical for autophagic cell death induced by CpG oligodeoxynucleotide 107 combined with irradiation in glioma cells.
    Li X; Cen Y; Cai Y; Liu T; Liu H; Cao G; Liu D; Li B; Peng W; Zou J; Pang X; Zheng J; Zhou H
    Sci Rep; 2016 Jun; 6():27104. PubMed ID: 27251306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of rabbit TLR9 by different CpG-ODN optimized for mouse and human TLR9.
    Liu J; Xu C; Liu YL; Matsuo H; Hsieh RP; Lo JF; Tseng PH; Yuan CJ; Luo Y; Xiang R; Chuang TH
    Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):443-51. PubMed ID: 22560893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytidine-phosphate-guanosine oligonucleotides induce interleukin-8 production through activation of TLR9, MyD88, NF-κB, and ERK pathways in odontoblast cells.
    He W; Zhang Y; Zhang J; Yu Q; Wang P; Wang Z; Smith AJ
    J Endod; 2012 Jun; 38(6):780-5. PubMed ID: 22595112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional expression of TLR9 in esophageal cancer.
    Zhang Y; Wang Q; Ma A; Li Y; Li R; Wang Y
    Oncol Rep; 2014 May; 31(5):2298-304. PubMed ID: 24647486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pivotal role of ADP-ribosylation factor 6 in Toll-like receptor 9-mediated immune signaling.
    Wu JY; Kuo CC
    J Biol Chem; 2012 Feb; 287(6):4323-34. PubMed ID: 22170068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
    Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
    Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor.
    Yao Y; Li J; Qu K; Wang Y; Wang Z; Lu W; Yu Y; Wang L
    Cancer Immunol Immunother; 2023 May; 72(5):1103-1120. PubMed ID: 36326892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.
    Nørgaard NN; Holien T; Jönsson S; Hella H; Espevik T; Sundan A; Standal T
    J Immunol; 2010 Sep; 185(6):3131-9. PubMed ID: 20702733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
    Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
    J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
    Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
    Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.